BioNTech SE Sponsored ADR $BNTX Position Decreased by GSK plc

GSK plc lowered its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 24.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 668,526 shares of the company’s stock after selling 221,298 shares during the quarter. BioNTech accounts for 13.2% of GSK plc’s investment portfolio, making the stock its 4th largest position. GSK plc’s holdings in BioNTech were worth $65,716,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new position in BioNTech in the second quarter worth approximately $39,000. Farther Finance Advisors LLC lifted its position in shares of BioNTech by 31.5% during the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after purchasing an additional 118 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of BioNTech by 50.3% in the third quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock valued at $83,000 after purchasing an additional 282 shares during the period. Quintet Private Bank Europe S.A. boosted its stake in shares of BioNTech by 232.8% in the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock valued at $188,000 after purchasing an additional 1,341 shares during the period. Finally, Sei Investments Co. acquired a new position in shares of BioNTech in the first quarter valued at approximately $220,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several research reports. UBS Group dropped their price target on shares of BioNTech from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Bank of America reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Morgan Stanley lowered their target price on BioNTech from $114.00 to $106.00 and set an “overweight” rating for the company in a research note on Wednesday, November 4th. Finally, Canaccord Genuity Group lowered their target price on BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.27.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $87.65 on Thursday. The stock has a market cap of $22.17 billion, a P/E ratio of -12.80 and a beta of 1.28. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The stock has a 50 day moving average of $93.80 and a two-hundred day moving average of $96.25. The company has a current ratio of 8.55, a quick ratio of 8.52 and a debt-to-equity ratio of 0.01.

BioNTech Company Profile

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.